about
Supramolecular Complexation of Carbohydrates for the Bioavailability Enhancement of Poorly Soluble DrugsBiosafe nanoscale pharmaceutical adjuvant materialsCollaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 diseaseThe Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short OverviewImportance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipientsOral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulationsCharacterization of albendazole-randomly methylated-β-cyclodextrin inclusion complex and in vivo evaluation of its antihelmitic activity in a murine model of TrichinellosisHydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen.Downscaling drug nanosuspension production: processing aspects and physicochemical characterization.Binding of sulfamethazine to β-cyclodextrin and methyl-β-cyclodextrinInteraction of fentanyl with various cyclodextrins in aqueous solutions.Innovative oral spray-dried Idebenone systems to improve patient compliance.Changes in the Physicochemical Properties of Piperine/β-Cyclodextrin due to the Formation of Inclusion ComplexesEtodolac/cyclodextrin formulations: physicochemical characterization and in vivo pharmacological studies.Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel.A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesSupramolecular architecture of tetrathiafulvalene-bridged bis(β-cyclodextrin) with porphyrin and its electron transfer behaviors.Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity.Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake.Difluorobenzocyclooctyne: synthesis, reactivity, and stabilization by beta-cyclodextrin.Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin.Titanocene / cyclodextrin supramolecular systems: a theoretical approach.Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.Liposome-encapsulated EF24-HPβCD inclusion complex: a preformulation study and biodistribution in a rat model.Preparation and evaluation of lidocaine hydrochloride in cyclodextrin inclusion complexes for development of stable gel in association with chlorhexidine gluconate for urogenital useAssessment of cultivation factors that affect biomass and geraniol production in transgenic tobacco cell suspension cultures.Supramolecular interactions of nonsteroidal anti-inflammatory drug in nanochannels of molecular containers: a spectroscopic, thermogravimetric and microscopic investigation.Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl-ß-cyclodextrin causes renal toxicity.Bioactive ZnO Coatings Deposited by MAPLE-An Appropriate Strategy to Produce Efficient Anti-Biofilm Surfaces.Improvement of Meloxicam Solubility Using a β-Cyclodextrin Complex Prepared via the Kneading Method and Incorporated into an Orally Disintegrating TabletDevelopment and optimization of a meloxicam/β-cyclodextrin complex for orally disintegrating tablet using statistical analysis.2D-Cosy NMR Spectroscopy as a Quantitative Tool in Biological Matrix: Application to Cyclodextrins.Investigation of Inclusion Complex of Patchouli Alcohol with β-CyclodextrinThe formation of a host-guest inclusion complex system between β-cyclodextrin and baicalin and its dissolution characteristics.Enhanced dissolution and stability of lansoprazole by cyclodextrin inclusion complexation: preparation, characterization, and molecular modelingA novel drug-phospholipid complex enriched with micelles: preparation and evaluation in vitro and in vivo.Molecular modeling-based inclusion mechanism and stability studies of doxycycline and hydroxypropyl-β-cyclodextrin complex for ophthalmic delivery.Approaches for enhancing oral bioavailability of peptides and proteins
P2860
Q26777831-4934B6EF-6841-4D9C-B66A-2C18F996EAE0Q26829798-8BE51D12-CB69-4221-A2FF-632360BF0BC7Q27006029-38E619FC-8B2A-4C83-B430-8F55429FC187Q28076502-189447CC-4B58-4AA3-A92B-8801BCB98DF8Q28082369-447A9CE9-D544-421B-94F3-75B1131C76EEQ28534686-004A4A9C-EFF4-4B36-9900-31B443D0AB7CQ28545036-A4FFA754-5376-43A4-BEB3-ED4909ED2472Q30371719-7979C8C8-AC68-4416-81CA-370286AADD4CQ30478736-6AB02A19-3B0D-4AD1-BF45-E45EC97E9222Q30619353-1AB9AB12-DB1E-42A3-945A-D83B3D7B637CQ30972595-0C9E6A48-5FE0-4B29-B075-FDC1C4D2FC27Q31021104-78BE9FC0-7C8E-4C53-A1BC-338BD34823C0Q31061194-FB4C6E21-3F77-4F9C-B34F-3B2892B659D2Q33452151-DD6FEEA8-0ADF-406A-8744-CF94A667E6EDQ33563610-9F3EC5DE-4025-4F16-A223-95D836775617Q33623674-C961A72E-C84B-46F5-9705-8736BF8078F4Q33683206-FD692F5B-DAA1-4EF3-856A-41F0B81FEDF6Q33734702-9ECD5C2E-F1E6-4F2B-B0CC-095877A2EC6FQ33803717-A8A83207-7722-4822-B60F-AB7277AB9C3DQ34019895-F3D44036-C7A2-4D39-8D70-16F9FA47C216Q34071871-A71F19CC-2F30-4B9A-B52B-F8F460718C16Q34072621-6A860BB8-D454-457E-89AC-5AE3B5A41B19Q34353491-0E6330E8-52A9-4D53-92CC-75C097D11175Q34466024-B8EE6929-B4DF-435A-89C6-57A8CCA99699Q35100405-929B3D0C-2018-43DF-BB65-7935D098226CQ35110669-0E0D8FE8-87F7-45E3-8352-0C953C39CD42Q35143230-607AF7F6-2021-4B30-B119-C18D1EB0A04DQ35223623-C27CEBFB-A8D9-4CFC-B132-9DEF82C8AB69Q35229443-31DCF236-E10B-467D-85C5-5A464937C23CQ35626401-6CDFC4FC-7448-4561-BD09-2913017EF0ECQ35927526-1C8BB0EF-01C0-489D-BD77-06289A8DEADEQ36170099-19570761-A01A-4E45-9706-FE26DD562A24Q36201299-3053E386-FF14-469D-8AD5-A7A4027F288FQ36232503-1E23AB44-E8CE-41B7-AAC9-DD0DD9A09B3AQ36251199-3F9EF7FE-3EE9-4590-9935-F9272E8F0B77Q36310011-CC868C89-4A68-4D1A-9FE0-DCDE06983EEDQ36442107-4467CC00-7EF3-4FD2-BA38-99AC10B48DF4Q36617816-3D3527E9-F172-4917-9A65-8D91A298456CQ36636481-460C5D90-EAFB-42F6-B4BD-7C8AA8500C88Q36922557-3AFECEFF-6F2B-4048-BC39-49B1220FBBC4
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cyclodextrins as pharmaceutical solubilizers.
@en
type
label
Cyclodextrins as pharmaceutical solubilizers.
@en
prefLabel
Cyclodextrins as pharmaceutical solubilizers.
@en
P1476
Cyclodextrins as pharmaceutical solubilizers
@en
P2093
Marcus E Brewster
P304
P356
10.1016/J.ADDR.2007.05.012
P407
P577
2007-05-29T00:00:00Z